Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA β ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia.

Autor: Dominguez JC; St Luke's Medical Center, Institute for Neurosciences, Philippines.; Institute for Dementia Care Asia, Philippines.; St. Luke's College of Medicine William H. Quasha Memorial, Philippines., Yu JRT; St Luke's Medical Center, Institute for Neurosciences, Philippines., De Guzman MF; Institute for Dementia Care Asia, Philippines.; Research and Biotechnology Division, St. Luke's Medical Center, Philippines., Ampil E; St Luke's Medical Center, Institute for Neurosciences, Philippines.; Institute for Dementia Care Asia, Philippines.; Department of Neuroscience and Behavioral Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Philippines., Guevarra AC; Institute for Dementia Care Asia, Philippines., Joson ML; St Luke's Medical Center, Institute for Neurosciences, Philippines.; Institute for Dementia Care Asia, Philippines.; Department of Neuroscience and Behavioral Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Philippines., Reandelar M Jr; Institute for Dementia Care Asia, Philippines.; Research and Biotechnology Division, St. Luke's Medical Center, Philippines.; Far Eastern University, Dr. Nicanor Reyes Medical Foundation, Philippines.; Our Lady of Fatima University, Philippines.; New Era University College of Medicine, Philippines., Martinez MS; St Luke's Medical Center, Institute for Neurosciences, Philippines.; St. Luke's College of Medicine William H. Quasha Memorial, Philippines., Ligsay A; St. Luke's College of Medicine William H. Quasha Memorial, Philippines.; College of Science and the Graduate School, University of Santo Tomas, Philippines., Ocampo F; Institute for Dementia Care Asia, Philippines., Kim S; Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Jazyk: angličtina
Zdroj: International journal of Alzheimer's disease [Int J Alzheimers Dis] 2022 May 02; Vol. 2022, pp. 9960832. Date of Electronic Publication: 2022 May 02 (Print Publication: 2022).
DOI: 10.1155/2022/9960832
Abstrakt: With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid- β (MDS-OA β ) is a noninvasive blood-based biomarker utilized to measure A β oligomerization tendency. We determined the difference in MDS-OA β ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OA β level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OA β level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2022 Jacqueline Cotoong Dominguez et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje